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The M. tuberculosis phosphate-binding transporter lipoproteins PstS1 and PstS3 were good immunogens inducing CD8+ T-cell
activation and both Th1 and Th17 immunity in mice. However, this antigen-speciﬁc immunity, even when ampliﬁed by
administration of the protein with the adjuvant LTK63 or by the DNA priming/protein boosting regimen, was not able to contain
M. tuberculosis replication in the lungs of infected mice. The lack of protection might be ascribed with the scarce/absent capacity
of PstS1/PstS3 antigens to modulate the IFN-γ response elicited by M. tuberculosis infection during which, however, PstS1-speciﬁc
IL-17 secreting cells were generated in both unvaccinated and BCG-vaccinated mice. In spite of a lack of protection by PstS1/PstS3
immunizations, our results do show that PstS1 is able to induce IL-17 response upon M. tuberculosis infection which is of interest
in the study of anti-M. tuberculosis immunity and as potential immunomodulator in combined vaccines.
1.Introduction
Tuberculosis (TB) remains a leading human infectious dis-
easeandamajorpublichealthprobleminlow-incomecoun-
tries [1]. Despite the availability of the Bacillus Calmette-
Gu´ erin (BCG) vaccine for more than 80 years, until now
an eﬀective tuberculosis vaccine is still unavailable and
still unknown are the correlates of protection against this
disease [2]. Several protective antigens in particular those
belonging to the immunodominant complex Ag85 [3–5]
have been studied but immune responses against most of
them are still not precisely deﬁned. Hence, the search for
new protective Mycobacterium tuberculosis (M. tuberculosis)
antigensremainavitalﬁeld,particularlyforproteinsexposed
on the bacterial cell surface exerting important physiological
functions and/or acting as virulence factors.
We recently focused our attention on phosphate-speciﬁc
transporter (pst) lipoproteins of M. tuberculosis.P s ti s
a membrane-associated complex that belongs to the ABC
transportersuperfamily[6].InM.tuberculosis,threeputative
pst operons have been identiﬁed pstS1, pstS2, and pstS3 [7],
which probably constitute a subtle biochemical adaptation
of this microorganism for its growth and survival under
diﬀerent phosphate-limiting conditions during its infectious
cycle [8]. The three genes coding these proteins are very
similar (about 75% similarity between pstS1 and pstS2 or
pstS3 and 94% similarity between PstS2 and PstS3), and
all proteins have a lipoprotein consensus signal [8]. These
phosphate transport receptors are exposed not only on the
cell surface of M. tuberculosis but also on the surface of
M. bovis BCG [8].
Disruption of genes encoding pstS1 and pstS2 reduced
in vivo multiplication of M. tuberculosis suggesting that
the high-aﬃnity phosphate-speciﬁc transporters are also
virulence factors of M. tuberculosis and M. bovis [9]. Speciﬁc
immunity against PstS lipoprotein has been detected in TB
patients, and in particular antibodies (Abs) against PstS1
have been reported to be a valuable tool in the serodiagnosis2 Clinical and Developmental Immunology
of active TB [10–12]. Moreover, mice vaccinated with DNA
coding for pstS3 demonstrated signiﬁcant and sustained
reduction in bacterial load in spleen and lungs for 3
months after M. tuberculosis challenge, as compared with
CFU counts in control unvaccinated mice [13]. Conversely,
immunizations with DNA coding for pstS1 resulted in con-
tradictory evidence regarding protection [13, 14] possibly
due to diﬀerent plasmid vector backbone and diﬀerent
experimental protocol of immunization and infection.
In this paper, we have reassessed the role of PstS3 and
PstS1 antigens on B and T cell-mediated immunity and
protection against M. tuberculosis infection. To expand and
diversify the immune responses induced by immunizations
with DNA only, we used a combination of DNA and protein
in a prime-boosting regimen and also the protein adminis-
tered with the adjuvant LTK63. In fact, our previous studies
on Ag85B, an abundant secreted protein of replicating
MTB which is currently evaluated in various TB vaccine
formulations [5], revealed that antigen-speciﬁc immunity
can be enhanced by priming/boosting regimen [3]. In
addition, the potent mucosal as well as systemic adjuvant
LTK63, a nontoxic derivative of heat-labile enterotoxin of
Escherichia coli [15], can exert positive and negative control
on Ag85B-speciﬁc Th1 polarization [4, 5]. The attention
was focused especially on the Th1 and Th17 responses, in
view of their relevant role in TB immunity. The importance
of IFN-γ-producing CD4+ T cells in primary resistance to
M. tuberculosis has been established both in humans and
mice [16–18]. IL-17, a proinﬂammatory cytokine mostly
produced by Th17 cells, can provide IFN-γ-dependent or
IFN-γ-independent protection to M. tuberculosis infection
[19, 20]. On the other hand, both the IFN-γ- and/or IL-17-
induced inﬂammation needs to be tightly controlled during
M. tuberculosis infection otherwise they can have important
pathological consequences [20–24].
Therefore the aim of the work was to dissect the PstS1-
and PstS3-speciﬁc immunity, through the use of diﬀerent
protocols of immunizations, suitable to the identiﬁcation of
protectiveresponses.Someoftheimmuneresponsesinduced
by PstS1 and PstS3 have been compared with those induced
by Ag85B, taken as protective antigen.
2.MaterialsandMethods
2.1. Ethics Statement. The handling of mice was conducted
in accordance with the regulations set forward by the
institutional animal care committee of the Italian Ministry
of Health, and in compliance with European Community
Directive 86/609 and the US Association for Laboratory
Animal Care recommendations for the care and use of
laboratory animals.
2.2. Microorganisms. M. tuberculosis H37Rv (ATCC 27294)
and M. bovis BCG strain Pasteur (ATCC 27291) were
grown at 37◦C in Middlebrook 7H9 medium supplemented
with albumin-dextrose-catalase enrichment under agitation
(120rpm) up to mid-exponential phase. Aliquoted stocks
were stored at −70◦C until use; the titers of stocks were
veriﬁed on a regular basis by counting the numbers of colony
forming unit (CFU) on Middlebrook 7H10 agar plates.
For the manipulation of plasmids, Escherichia coli (E. coli)
(strains: MC1061, K12 CAG629, and Rosetta) was grown
on Luria-Bertani (LB) broth or agar supplemented with
ampicillin (100μg/mL), as required.
2.3. Production of DNA-PstS1, DNA-PstS3, or DNA-Ag85B
Vaccines and Recombinant PstS1, PstS3, or Ag85B Proteins.
Plasmid DNA coding for PstS1 or PstS3 was prepared as
previously described [13, 14, 25]. Brieﬂy, plasmid DNA
was isolated from E. coli host strains by standard plasmid
preparation technique using the QIAGEN Plasmid Maxi Kit
according to the manufacturers recommendations. Bacteria
were cultured over night in LB Broth containing the appro-
priate antibiotics. Following plasmid isolation, the quality
of DNA was determined using agarose gel electrophoresis.
All plasmid DNA contained their own signal sequence and
the human tpa signal sequence. The plasmid sequences were
veriﬁed by DNA sequencing. Recombinant PstS1 protein
was prepared in E. coli strain K12 CAG629 containing the
expression plasmid for recombinant PstS1 [25]. After cell
disruption by sonication, the inclusion body bound protein
wassolubilizedinbuﬀercontaining8Mureaandrefoldedby
gelﬁltrationonSephadexG25ﬁnemedium(GEHealthcare).
Protein contaminants were separated from PstS1 by per-
forming anion exchange chromatography using Q Sepharose
High Performance (GE Healthcare). The protein solution
was concentrated by crossﬂow ﬁltration with a module
of 100kDa molecular weight cutoﬀ to a concentration of
approximately 1mg/mL. Finally a buﬀer exchange step into
volatile buﬀer was performed by gel ﬁltration on Sephadex
G25 ﬁne medium (GE Healthcare), and the protein was
freeze dried. Recombinant PstS3 protein was prepared in E.
coli strain Rosetta (DE3) (Novagen) containing the expres-
sion plasmid for recombinant PstS3. Cells were grown in LB
medium in shaking ﬂasks at 37◦C and induced with 1mM
I P T G .4 ha f t e ri n d u c t i o nc e l l sw e r eh a r v e s t e d .A f t e rc e l l
disruption by sonication the inclusion body bound protein
wassolubilizedinbuﬀercontaining8Murea.Ametalchelate
aﬃnity chromatography under denturating conditions was
performed (Ni-NTA resin, QIAGEN), and bound protein
was eluted in an increasing imidazole gradient. PstS3 con-
taining fractions were refolded by gel ﬁltration on Sephadex
G25 ﬁne medium (GE Healthcare) in potassium phosphate
buﬀer. The refolded protein was concentrated using VivaCell
concentrators (10kDa molecular weight cutoﬀ;S a r t o r i u s
stedim) to a concentration of approximately 150μg/mL and
stored at 4–8◦C. The LPS content of all protein preparations
was measured by a Lymulus amebocyte lysate test and shown
to be below 4.3EU/μg of protein.
Recombinant Ag85B protein and plasmid DNA coding
for Ag85B were prepared as previously described in [3, 4].
2.4. Immunization and Mycobacterial Infection. C57BL/6
female mice were supplied as speciﬁc pathogen-free mice
by Harlan (Udine, Italy) and were maintained in speciﬁc
pathogen-free conditions. Food and water were available
ad libitum. Seven- to 8-week-old mice were immunized.
Fifty μg of plasmid DNA-pstS1,D N A - pstS3,o rD N A - Ag85BClinical and Developmental Immunology 3
was injected i.m. in 50μl PBS into the hind leg. On the
dorsum of the mice, 10μg of recombinant PstS1, PstS3, or
Ag85B protein was administered s.c with or without 10μg
LTK63 (Novartis Vaccine and Diagnostics Srl, Siena, Italy).
Mice were immunized, at 2-week intervals, 2 or 4 times
with DNA, and 2 times with recombinant protein alone
or together with LTK63 adjuvant. Some mice were boosted
twice with recombinant Ag85B protein coadministered with
LTK63 adjuvant after priming with DNA. As a positive
control, a single dose of BCG (105 CFU) was injected s.c.
(Figure 1).
Four weeks after the last immunization, mice were chal-
lengedi.v.inalateraltailveinwith105 CFUofM.tuberculosis
H37Rv. Infection studies were performed in a biosafety level
3 facility; mice were housed in microisolator cages and fed
with autoclaved food and water at libitum. After 4 weeks, the
mice were killed by cervical dislocation, and the number of
bacteriainlungswasenumeratedbyhomogenizingthetissue
and plating 10-fold dilutions, prepared in distilled water, on
Middlebrook 7H10 agar. The colonies were counted visually
after 21 days of incubation.
2.5. Antibody Measurement. Sera from immunized mice
were collected by retro-orbital bleeding 4 weeks after the last
immunization. The levels of total anti-PstS1 and anti-PstS3
IgG antibodies (Abs) were determined by ELISA. Brieﬂy,
polyvinyl microtiter plates (Nunc) were coated overnight at
4◦Cw i t h1 0μg/mL each recombinant antigen (PstS-1, PstS-
3) in PBS. Several dilutions of mouse serum were incubated
for 45min at 37◦C prior to the addition of antimouse
immunoglobulin G-peroxidase conjugate and then tetram-
ethylbenzidine substrate. The mean absorbance of naive
mouse sera, diluted 1:100, plus 3 standard deviations was
adopted as the cutoﬀ absorbance for determining Ab titers.
2.6.SplenocytePreparationandCellCulture. Fourweeksafter
the last immunization, single cell suspensions were prepared
from the pooled spleens (3 mice/group), passed through
Falcon 2360 cell strainers (BD Discovery Labware), cen-
trifuged, aliquoted, and then frozen in liquid nitrogen. Some
spleen cells were prepared from unvaccinated mice or BCG-
vaccinated mice infected with M. tuberculosis as described
above. Spleens of infected mice were recovered after 4 or 11
weeks from the challenge and processed in a biosafety level
3 facility. From single spleen cell suspensions, depletion of
CD4+ T-cell population was obtained by the magnetically
labeled fractions isolated from the speciﬁc mouse CD4+T-
cell isolation kits (Miltenyi Biotec Inc., Auburn, CA), in
accordance with the manufacturer’s instructions. By FACS
analysis, negligible ﬂuorescence was observed in depleted
fractions during the labeling of cells with the monoclonal Ab
CD4-PE corresponding to the depleted cell population. Cells
isolated from spleens of na¨ ıve, vaccinated, or MTB-infected
mice were cultured at 4 × 105/200μl in 96-well ﬂat plates
in RPMI-1640 supplemented with 10% heat-inactivated
FBS, 2mM L-glutamine, 10mM HEPES buﬀer, 50μM2 - β-
Mercaptoethanol, 50U/mL penicillin, and 50μg/mL strepto-
mycin(completeRPMI,cRPMI)andstimulatedwithAg85B,
PstS1, or PstS3 proteins (5μg/mL each).
2.7. Cytokine Detection. Culture supernatants after 4 days
of culture were assayed for IFN-γ and IL-17, by speciﬁc
quantitative sandwich ELISA Kits (mouse Quantikine, R&D
System, Inc., Minneapolis, MN), in accordance with the
manufacture’s instructions. Quantitation was made against
a standard curve obtained for individual cytokine standards
provided by the manufacturer.
2.8. Cell Proliferation by CFSE Staining. Spleen cells
(107 cells/mL) were stained with 5(6)-Carboxyﬂuorescein
diacetate N-succinimidyl ester (CFSE) (Invitrogen Life Tech-
nologies) at 1μM in PBS 1% FBS for 10min at 37◦Ci nt h e
dark. Cells were washed and cultured in 96-well plates, as
previously described, for 4 days. After the incubation time,
cells were washed with FACS buﬀer and stained for 20min
at 4◦C with PE antimouse CD4 and PerCP antimouse CD8,
(BD Biosciences Pharmingen) or the isotype controls. Cells
werewashedandanalyzedonaFACScanﬂowcytometerwith
the Cell Quest software programs.
2.9. Cell Proliferation by H3-Thymidine Incorporation.
After 4 days of culture, the cells were pulsed with
[H3]thymidine (1μCi/well) (Perkin Elmer Life and Analyti-
cal Sciences, Boston, MA) for additional 18h. Incorporation
of [H3]thymidine was measured by β-scintillation counting
(Microβ counter, Perkin Elmer). Values were expressed as
mean counts per minute (cpm) in the cultures.
3. Results
3.1. Immunization with Protein Was Required to Induce
Speciﬁc Anti-PstS1 or Anti-PstS3 Ab Responses, with PstS1
Being a Better Inducer. In a ﬁrst series of experiments,
mice were immunized with the antigens PstS1 and PstS3
by using several protocols of immunizations, as reported
in Figure 1. In particular, DNA was given two or four
times, protein, alone or together with LTK63 adjuvant,
two times, and priming with two DNA injections and
boosting with the protein in LTK63 adjuvant twice. These
protocols were selected based on previous work made with
the immunodominant M. tuberculosis antigen Ag85B, which
generated diﬀerential humoral and cell-mediated responses
associated or not with protection against M. tuberculosis
challenge (Table 1).
Four weeks after the last immunization, the sera were
analyzed for speciﬁc anti-PstS1 or anti-PstS3 immunoglob-
ulins (Ig) (Figures 2(a) and 2(b)). Speciﬁc IgG were detected
exclusively in mice receiving protein with or without adju-
vant. PstS1 antigen was a good inducer of antigen-speciﬁc
Ab response while the Ab-speciﬁc production in mice
immunized with PstS3 was very weak. In addition, in mice
immunized with PstS1 the adjuvant LTK63 greatly enhanced
the anti-PstS1 Ab production, and a cross-reactivity with
PstS3 antigen was also observed. On the other hand, in
mice immunized with PstS3 antigen the antigen-speciﬁc IgG
titer was minimally enhanced by the adjuvant LTK63 and
no cross-reactivity with PstS1 antigen was found. These
data suggested a superior capacity of PstS1 to act as cross-
stimulating Ab inducer.4 Clinical and Developmental Immunology
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Figure 1: Schematic diagram of experimental design. C57BL/6 female mice were immunized twice or four times at 2-week intervals, with
plasmid DNA (coding for pstS1, pstS3, or ag85B) or recombinant proteins (PstS1, PstS3, or Ag85B) in the presence or absence of LTK63
adjuvant. As a positive control, a single dose of BCG was injected s.c. Four weeks after the last immunization, mice were challenged i.v. with
105 CFU of M. tuberculosis H37Rv or killed to recover blood and spleen. Control: naive C57BL/6 female mice receiving PBS; DNA: plasmid
DNA coding pstS1, pstS3, or ag85B 50μg/injection i.m.; protein: PstS1, PstS3, or Ag85B proteins 10μg/injection s.c.; protein/LTK63: PstS1,
PstS3, or Ag85B protein together with the adjuvant LTK63 10μg each/injection s.c.; BCG: BCG Pasteur 105 CFU s.c.
Table 1: Eﬀects of diﬀerent immunizations with the mycobacterial antigen Ag85B on protection against Mycobacterium tuberculosis
challenge and antigen-speciﬁc immunity in mice.
Immunizationsa IgG titerb Cell proliferation (cpm)c IFN-γ (pg/mL)d IL-17 (pg/mL)e −Δ CFU(log)/protectionf Referenceg
DNA x2 800 ±200 3500 ±300 450 ±30 0 ±0 −0.7/yes [3]
DNA x4 2000 ±350 3937 ±1064 559 ±60 0 ±0 −0.74/yes [3]
DNA/protein-LTK63 43053 ±4746 22037 ±2695 6214 ±168 320 ±52 −0.32/yes [4]
protein-LTK63 64507 ±12388 16714 ±326 3839 ±150 420 ±90 −0.31/yes
protein 2800 ±542 7579 ±645 333 ±100 10 ±5 −0.02/no [3]
BCG −1.1/yes [3, 4]
amice (5 mice/group) were immunized with Ag85B according to Figure 1, and some mice challenged also with M. tuberculosis H37Rv.
bsera of immunized mice recovered 4 weeks from the last immunizations were analyzed by ELISA for the presence of anti-Ag85B Ab using a conjugated
secondary Abs speciﬁc total IgG. Data are plotted as geometric mean ELISA titer ± SEM of 3 independent experiments.
cspleen cells of Ag85B-immunizedmicewere cultured at 4×105 cells/well andre-stimulatedexvivowith Ag85B protein(5μg/mL) for 5 days before measuring
thymidine incorporation in proliferating cells. Cell proliferation data are represented as mean cpm (subtracted from the cpm of unstimulated spleenc e l l s )±
SEM of 3 independent experiments.
dspleencellsofAg85B-immunizedmicewereculturedat4×105 cells/well andre-stimulatedexvivowithAg85Bprotein(5μg/mL)for 4daysbefore measuring
in cell culture supernatants IFN-γ by a speciﬁc ELISA kit. IFN-γ data are represented as mean (pg/mL) ± SEM of 3 independent experiments.
espleen cells of Ag85B-immunizedmice were cultured at 4×105 cells/well andre-stimulated exvivowith Ag85B protein(5μg/mL) for 4 days before measuring
in cell culture supernatants IL-17 by a speciﬁc ELISA kit. IL-17 data are represented as mean (pg/mL) ± SEM of 3 independent experiments.
fAfter 4 weeks from M. tuberculosis challenge, the bacteria in the lung of infected mice were enumerated as described in Materials and Methods. Data are
expressed as the Δ in CFU/lung (log) between vaccinated and unvaccinated control mice and it is indicated whether or not the vaccination was protective
against M. tuberculosis challenge.
gReference reporting some of the data.
3.2. Antigen-Speciﬁc Cell Proliferation Was Mainly due to
CD8+ T Cells and Was Higher in PstS1- than in PstS3-Im-
munized Mice: PstS1 Fully Activated Cells of Mice Immunized
with PstS3 Antigen while the Eﬀect of PstS3 Re-Stimulation
Was Only Partial on Cells of PstS1-Immunized Mice. Spleen
cells of immunized mice were re-stimulated ex vivo with
PstS1 or PstS3 antigens and cell proliferation was measured
by thymidine incorporation in total spleen cells at 5 days
of culture or by CFSE dilution in CD4+ or CD8+ Tc e l l
populations after 4 days of culture (Figure 3).Clinical and Developmental Immunology 5
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Figure 2: PstS1 and PstS3-speciﬁc Ab production in immunized mice. Pooled serum samples (3 mice/group) of mice immunized with
antigen PstS3 (a) or PstS1 (b) were analyzed by ELISA for the presence of anti-PstS1 or anti-PstS3 Abs using a conjugated secondary Abs
speciﬁctotalIgG.Data,combinedfrom3independentexperiments,areplottedasgeometricmeanELISAtiter ±SEM. §Statisticalsigniﬁcant
diﬀerence among anti-PstS1 Ab titer and anti-PstS3 Ab titer in each group of immunized mice (P<. 05 or P<. 01 determined by a two-
tailed Student’s t-test); ◦statistical signiﬁcant diﬀerence in anti-PstS1 Ab titer between mice immunized with PstS1 protein alone and mice
immunized with protein together with LTK63 adjuvant, P<. 01 determined by a two-tailed Student’s t-test.
Spleen cells of both PstS1 or PstS3 immunized mice pro-
liferated in response to antigens with a greater contribution
of CD8+ T cells rather than CD4+ T cells (Figures 3(c),
3(e), 3(d),a n d3(f)). Proliferation was signiﬁcantly higher
by cells of mice immunized with protein rather than in cells
of mice immunized with DNA especially in mice immunized
with pstS1 antigen (Figures 3(a), 3(b),a n d3(f)). Moreover
in mice immunized with DNA only, CD8+ T cells were the
cells mainly involved in proliferation (Figures 3(e) and 3(f)).
While scarce or absent was the contribution of CD4+ T
cells (Figures 3(c) and 3(d)). Administration of either PstS1
or PstS3 protein with LTK63 adjuvant did not signiﬁcantly
modify the antigen-speciﬁc memory response. Here again,
some important diﬀerences between the two antigens were
found. Mice immunized with PstS1 showed a greater cell
proliferationcomparedtomiceimmunizedwithPstS3,while
an anti-PstS1-speciﬁc CD4+ T cell proliferation, although
weak, was found also in mice immunized with DNA only
(Figure 3(d)).
Cells of mice immunized with PstS1 proliferated also
in response to PstS3 antigen stimulation but the eﬀect was
restricted to CD8+ T cell population, and the proliferation
was signiﬁcantly lower than that induced by PstS1 re-
stimulation (Figure 3(f)). On the other hand, in cells of
mice immunized with PstS3 antigen the magnitude of
proliferation in response to both PstS1 and PstS3 antigen
re-stimulation was similar and PstS1 was even better in
re-activating CD8+ T cell proliferation in mice immu-
nized four times with DNA or in the group immunized
w i t hp r o t e i na n dL T K 6 3( Figure 3(e)). Moreover, CD4+
T cells of some PstS3 immunizations (DNA/proteinLTK63
and protein LTK63-immunized mice) were able to pro-
liferate in response to antigenic recall with PstS1 protein
(Figure 3(c)).
These data suggested that PstS1 and PstS3 also diﬀered in
the capacity to induce and/or recall antigen-speciﬁc memory
T cell proliferation.
3.3. PstS3 Antigen Was More Potent than PstS1 Antigen in
Generating Memory IFN-γ-Producing Cells but Only PstS1
Protein Induced IL-17. Spleen cells of immunized mice were
re-stimulated in vitro with PstS1 or PstS3 antigen and after 4
days the supernatants of culture were analyzed to detectIFN-
γor IL-17 by ELISA. All kind of immunizations generated
antigen-speciﬁc memory IFN-γ-secreting cells although the
secretion was very low in mice immunized with protein
alone or DNA only except in those animals receiving four
administrations of DNA coding for pstS3 (Figures 4(a)
and 4(c)). Administration of protein with LTK63 greatly
enhanced the IFN-γ response in the immunization with
PstS3 antigen (Figure 4(a)) while the increase was modest,
although still statistically signiﬁcant, in PstS1 immunizations
(Figure 4(c)). CD4+ T cells were mandatory for IFN-γ
production as indicated by CD4+ T cell-depletion studies
(Figures 4(e) and 4(f)). A weak cross-reactivity was observed
with the related protein in all immunizations. In general,
PstS3 antigen was a better inducer than PstS1 of memory
IFN-γ-producing cells.
The production of IL-17 was associated with the admin-
istration of PstS3 protein with adjuvant LTK63 (Figure 4(b)),
while immunization with PstS1 protein even in the absence
of adjuvant induced a speciﬁc Th17 response (Figure 4(d)).
The production of IL-17 was higher in PstS1 immunizations
compared to PstS3 immunizations. In PstS1-immunized
micetheratioofIL-17/IFN-γ washigheroraround1indicat-
ing that the amount of the two cytokines released was similar
(Figures 4(c) and 4(d)), while in PstS3 immunizations the
ratio was much lower than 1 since the production of IFN-γ6 Clinical and Developmental Immunology
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Figure 3: Cell proliferation in response to PstS1 or PstS3 proteins in spleen cells of immunized mice. Pooled spleen cells (3 mice/group) of
mice vaccinated with PstS3 antigen (panels (a), (c), and (e)) or with PstS1 antigen (panels (b), (d), and (f)) were cultured at 4×105 cells/well
and re-stimulated ex vivo with PstS1 or PstS3 proteins (5μg/mL each) for 5 days before measuring thymidine incorporation in proliferating
cells ((a) and (b)) or for 4 days before measuring CFSE dilution in replicating CD4+((c) and (d)) or CD8+ T cell populations ((e) and (f)).
Datawerecombinedfrom3independentexperimentsandarepresentedasmean.ErrorbarsindicateSEM.Thelevelofstatisticalsigniﬁcance
for diﬀerences in each group of immunized mice was determined by a two-tailed Student’s t-test (
∗P <. 05;
∗∗P <. 01 PstS1 or PstS3
stimulation versus unstimulated cells; §between PstS1- and PstS3-induced responses in each group; ◦between antigen-speciﬁc responses
observed in mice immunized with DNA or protein alone).
was always greater than IL-17 secretion (Figures 4(a) and
4(b)).
3.4. Neither PstS3 nor PstS1 Immunizations Reduced the
Mycobacterial Load in the Lungs of Mice Challenged with
M. tuberculosis. Four weeks after the last immunization,
and concomitantly with the assessment of antigen-speciﬁc
memory immune responses, groups of mice were challenged
with virulent M. tuberculosis and the bacterial load in
the lungs was measured 4 weeks after the challenge. In
parallel experiments, protection induced by immunization
with Ag85B under identical schedule was assessed (Table 1
[3, 4]). As shown in Figure 5, none of the vaccinations with
PstS1 or PstS3 antigens was able to reduce the bacterialClinical and Developmental Immunology 7
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Figure 4: Cytokine production in response to PstS1 or PstS3 proteins in spleen cells of immunized mice. Pooled spleen cells (3mice/group)
of mice vaccinated with PstS3 antigen (panels (a) and (b)) or with PstS1 antigen (panels (c) and (d)) were cultured at 4 × 105 cells/well and
re-stimulated ex vivo with PstS1 or PstS3 proteins (5μg/mL each) for 4 days before measuring IFN-γ ((a) and (c)) or IL-17 ((b) and (d)) in
thesupernatant of culturebyspeciﬁcELISAkit. Datawere combined from3independent experiments and arepresented as mean. Errorbars
indicate SEM. §Statistical signiﬁcant diﬀerence between PstS1- and PstS3-induced responses in each group of immunized mice (P<. 05 or
P<. 01 determined by a two-tailed Student’s t-test). In some experiments spleen cells of DNA x4-, DNA/protein-LTK63-, or protein/LTK63-
immunized mice with both PstS3 (e) or PstS1 (f) antigens were depleted of CD4+ T cells by using magnetic beads as described in Materials
and Methods. Undepleted cells and CD4+ T cell-depleted subset were re-stimulated with PstS1 or PstS3 protein (5μg/mL) for 4 days before
testing the IFN-γ by a speciﬁc ELISA kit ((e) and (f)). Error bars indicate SEM. The level of statistical signiﬁcance for diﬀerences among
undepleted cells and CD4+ T cell-depleted subset in each group was determined by Student’s t-test (
∗P <. 05;
∗∗P <. 01).8 Clinical and Developmental Immunology
Bacterial load in the lungs
4
4.5
5
5.5
6
6.5
U
n
v
a
c
c
i
n
a
t
e
d
B
C
G
Immunizations with PstS3 Immunizations with PstS1
D
N
A
x
2
D
N
A
x
4
P
r
o
t
e
i
n
D
N
A
/
p
r
o
t
e
i
n
-
L
T
K
6
3
P
r
o
t
e
i
n
-
L
T
K
6
3
D
N
A
x
2
D
N
A
x
4
P
r
o
t
e
i
n
D
N
A
/
p
r
o
t
e
i
n
-
L
T
K
6
3
P
r
o
t
e
i
n
-
L
T
K
6
3
C
U
F
(
l
o
g
)
/
l
u
n
g
Figure 5: Eﬀects of PstS1- or PstS3-immunizations on protection against M. tuberculosis challenge in mice. Mice (5 mice/group) were
immunized with PstS1 or PstS3 antigens according to Figure 1, and challenged with M. tuberculosis H37Rv. Four weeks after infection, the
bacteria in the lung were enumerated as described in Materials and Methods. Data are expressed as mean of the ﬁve individual mice ± SE.
The level of statistical signiﬁcance for diﬀerences between test groups and the control unvaccinated mice were determined by ANOVA test
(∗signiﬁcant).
load in the lungs of infected mice. On the contrary, BCG
vaccination (Figure 5 and Table 1) and all the several pro-
tocols of vaccination with the antigen Ag85, except only for
immunization with Ag85B protein in absence of adjuvant,
inducedsigniﬁcantprotectioninthelungsofM.tuberculosis-
infected mice (Table 1).
3.5. PstS1 and PstS3 Antigens in Contrast to Ag85B Were Not
Recognized by IFN-γ-Secreting Spleen Cells of M. tuberculosis-
Infected Mice: However PstS1 Stimulated IL-17 Production.
To explain why the phosphate-binding protein immuniza-
tions were unsuccessful in protection against M. tuberculosis
infection we investigated whether PstS1, or PstS3 speciﬁc
immune reactions were raised during M. tuberculosis infec-
tion in unvaccinated or BCG-vaccinated mice. Therefore
spleen cells of na¨ ıve unvaccinated or BCG-vaccinated mice
recovered before M. tuberculosis infection or after 4 or 11
weeks from M. tuberculosis challenge were re-stimulated ex
vivo with PstS1 or PstS3 proteins. Ag85B protein was also
assayed as a protective comparator. The IFN-γ-secreting
spleen cells of M. tuberculosis-infected mice responded to
Ag85B protein, and the production of IFN-γ was greatly
enhanced in mice vaccinated with BCG and infected for
4w e e k sw i t hM. tuberculosis (Figure 6). On the contrary,
neither PstS3 nor PstS1 antigens were able to induce IFN-
γ release by spleen cells of unvaccinated or BCG-vaccinated
mice infected with M. tuberculosis f o r4o r1 1w e e k s .
Therefore, despite that PstS1 and especially PstS3 were good
immunogens for activation of Th1 responses, the IFN-γ
responses generated during early or late time points of
M. tuberculosis infection (both in unvaccinated and BCG-
vaccinated mice) were insensitive to these antigens.
Completely diﬀerent results were obtained for IL-17-
secreting cells present in spleen cells of M. tuberculosis-
infected mice. In fact, PstS1, but not PstS3, antigen stim-
ulated Th17 response in M. tuberculosis-infected mice. An
important production of IL-17 was found in spleen cells of
unvaccinated mice infected with M. tuberculosis for 4 weeks
and the PstS1-responding IL-17-secreting cells decreased
with progression of M. tuberculosis infection. In mice
vaccinated with BCG and infected with M. tuberculosis the
PstS1-activated IL-17 response was similar at the two time
points of infections. Moreover, PstS1 was a better inducer
than Ag85B of Th17 response in M. tuberculosis-infected
mice.
4. Discussion
The medical need of identifying new candidate antigens for
vaccine development against TB led us to investigate the
phosphate-binding transporter proteins of M. tuberculosis.
In fact, these membrane lipoproteins have been reported to
be virulence factors for M. tuberculosis [9], are expressed
also on surface of BCG [8], and can induce speciﬁc immune
response in patients with active TB [10, 12, 26]. Importantly,
protection against M. tuberculosis challenge was reported
in mice immunized with plasmid DNA coding for pstS1
[14]o rpstS3 [13]. The aim of this paper was to reassess
immunogenicity and protective capacity of the above pro-
teins by using diﬀerent protocols of vaccinations with PstS1
and PstS3 to diversify the antigen-speciﬁc immune response.
Moreover, the data were compared with a well-known
immunogenic and protective antigen, the Ag85B [3–5]. We
noticed that both PstS1 and PstS3 are capable of inducing,
to a various degree and magnitude, a number of immune
responses which are usually considered to be relevant for
immune protection, including activation of T cell-mediated
immunity as exempliﬁed by CD4+ and/or CD8+ T-cell
proliferation and production of diﬀerent amount of IFN-γ
and/or IL-17. Although considered of scarce importance
in protection against M. tuberculosis infection, antigen-
speciﬁc humoral responses, especially in PstS1-immunized
mice, were also induced. Nonetheless, neither PstS1- nor
PstS3-immunized mice were protected from challenge with
M. tuberculosis, at variance with BCG- or Ag85B-immunized
mice. Lack of protection was observed regardless antigenClinical and Developmental Immunology 9
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Figure 6:PstS1-speciﬁcIL-17—butnotIFN-γ—secretingcellsweregeneratedduring M.tuberculosisinfection.Na¨ ıveunvaccinatedorBCG-
vaccinated mice (5 mice/group) were infected or not with M. tuberculosis for 4 or 11 weeks. Spleen cells recovered from mice were stimulated
ex vivo (4 × 105 cells/well) with PstS1, PstS3, or Ag85B proteins (5μg/mL each) for 4 days and culture cell supernatants assayed for IFN-γ
(a) or IL-17 (b) by speciﬁc ELISA kits. Data were combined from 3 independent experiments and are presented as mean. Error bars indicate
SEM.
formulation and expression, as protein or DNA or prime-
boostimmunization.Variationsinmethodologymayexplain
why other research groups have found DNA-pstS1 [14]a n d
DNA–pstS3 [13] protective: Zhu et al. [14] challenged DNA-
pstS1-immunized mice i.p. (not i.v.) with M. tuberculosis just
2 weeks (not 4 weeks) after the last booster. Tanghe et al. [13]
challenged DNA-pstS3-immunized mice with a higher (106
rather than 105 mycobacterial cells) M. tuberculosis burden
and this burden in the lungs was evaluated at 8 weeks (not 4
weeks).
Thescarce/absentinvolvementofPstS3andPstS1antigen
in the IFN-γ response, the essential arm of protective TB
immunity [16–19], mounted in response to M. tuberculosis
during natural infection may be the cause of ineﬃcacy of
vaccinations with these antigens. In fact, IFN-γ-secreting
cells generated following M. tuberculosis infection, both in
unvaccinated or BCG-vaccinated mice, did not respond to
antigenic stimulation with PstS1 or PstS3 proteins while they
were speciﬁc for the protective antigen Ag85B. The irrele-
vance of PstS3-speciﬁc IFN-γ immunity during M. tuber-
culosis infection was further conﬁrmed by the fact that
ampliﬁcation of this response by priming/boosting regimen
did not aﬀect the replication of M. tuberculosis compared to
unvaccinated or PstS3-vaccinated mice inducing low-IFN-γ
response.
Despite the fact that an s.c. immunization with PstS1
proteinprovedtobeanonprotective,itwasrecognizedbyIL-
17-secreting cells generated during M. tuberculosis infection.
The role of IL-17 in protection against M. tuberculosis
infection is not fully elucidated. Infection of IL17−/− mice
with M. tuberculosis revealed that IL-17 was not essential
to control the growth of M. tuberculosis during acute
infection [19] suggesting that IFN-γ-secreting CD4+ and
eﬀector CD8+ Tc e l l sw e r es u ﬃcient to inhibit mycobacterial
replication in the absence of IL-17. Recently, it has been
reported that M. bovis BCG-speciﬁc Th17 cells confer
partial protection against M. tuberculosis infection in the
absence of IFN-γ [20], indicating that also Th17 cells per
se, independently from IFN-γ response, may contribute
to the early control of M. tuberculosis infection. However,
the short-term protective eﬀect provided by the IL-17-
secreting cells occurred at the cost of increased tissue damage
characterized by a marked neutrophil inﬁltrate [20]. In this
context, one aspect of Th17 response is particular attracting
in TB vaccination. IL-17 accelerates antigen-speciﬁc Th1
memory response in the lungs of vaccinated mice infected
with M. tuberculosis [19]. One of the central improvements
required in the development of eﬀe c t i v eT Bv a c c i n e si st o
shorten the delay in recruitment of antigen-speciﬁc Th1
cells in the lungs. Therefore, the immunogenic feature of
PstS1 antigen to induce Th17 responses recognized during
M. tuberculosis infection should be further investigated in TB
vaccine development to study whether PstS1 given in com-
bination with antigens inducing protective Th1 immunity
could accelerate the expression of protective Th1 immunity
in the lungs upon infection.
Another aspect of immunogenic features of PstS1
deserves to be further investigated. PstS1, even in the
immunization schedules with protein alone, activated CD8+
T-cell proliferation even better than the CD4+ T-cell coun-
terpart. Although the role of these PstS1-speciﬁc CD8+
T cells appears not uncoupled with a direct eﬀect on
protection, these cells might participate in the network of
cellular regulation during infection. In fact, in addition to
a recognized, direct role in protection against TB through
their cytotoxic activity on M. tuberculosis-infected cells [27],10 Clinical and Developmental Immunology
CD8+ Tcellsspeciﬁcformycobacterialantigens cansuppress
IFN-γ production and proliferation by CD4+ Tcells[28, 29].
LTK63 is a good adjuvant improving protection when
used in vaccination with protective TB antigens [4, 5]. In
vaccinations with antigen Ag85B, LTK63 improved protec-
tionagainstM.tuberculosischallengebymodulatingmemory
IFN-γ-secreting CD4+ T cells with opposite eﬀects. The
INF-γ response was enhanced in unprimed mice vaccinated
with Ag85B protein and adjuvant (Table 1)b u tr e d u c e di n
mice primed with DNA and boosted with protein associated
with the adjuvant [4]. In the latter case, coadministration
of Ag85B protein with the adjuvant LTK63 reduced the
generation of nonprotective Ag85B-speciﬁc IFN-γ-secreting
cells, that led to a partial recovery in protection [4]. In
fact,inDNA-primedmiceboostedwithadjuvant-freeAg85B
protein, the expansion of an Ag85B-speciﬁc CD4+ T-cell
subset secreting elevated IFN-γ amounts was associated with
the loss of that protection conferred by immunization with
DNA only [3]. Now we also report that LTK63 drives the
commitment of memory antigen-speciﬁc T cells towards
Th17 response, as observed not only in Ag85B but also in
PstS1 and PstS3 immunizations. Considering that IFN-γ and
IL-17 responses are negatively regulated by each other [30–
32], the induction at the same time of both responses may
help to prevent that one response, at the expense of the
other, can expand without control causing inﬂammation-
mediated lung damage during M. tuberculosis infection.
In fact, the balance between protection and pathological
consequences is the crux of TB pathogenesis. The ability
to activate several mechanisms to contain uncontrolled
expansionofTh1/Th17-mediatedinﬂammatoryprocessmay
be the reason of the eﬃcacy of LTK63 adjuvant in TB
vaccination.
5. Conclusion
WedemonstratedthattheM.tuberculosisphosphate-binding
transporter lipoproteins PstS1 and PstS3 are excellent
immunogens inducing CD8+ T-cell activation and both Th1
and Th17 immunity. These antigen-speciﬁc responses were
not able, however, to contain M. tuberculosis replication
in the lungs of infected mice even when ampliﬁed by
administration of the protein with the adjuvant LTK63
or by the DNA priming/protein boosting regimen. The
lack of protection might be ascribed to the scarce/absent
immunogenicity/presentation of these antigens during natu-
ral infection. In fact, neither IFN-γ- nor IL-17-secreting cells
speciﬁc for PstS3 were generated in spleen of unvaccinated
or BCG-vaccinated mice infected with M. tuberculosis. Also
PstS1 antigen, a weak inducer of Th1, did not react with
IFN-γ-secreting cells generated during early or late infection
with M. tuberculosis. However, although not determinant for
protection, PstS1-speciﬁc IL-17-secreting cells were gener-
ated during M. tuberculosis infection both in unvaccinated
andBCG-vaccinatedmice.AlthoughPstS1isanonprotective
antigen “per se,” it could be utilized in TB vaccination, as
modulator, in association with antigens making protective
Th1 immunity. In fact, the PstS1 ability to drive Th17
immunity recognized upon M. tuberculosis infection could
accelerate the recruitment of protective IFN-γ cells in the
lungsofinfectedanimals.Toshortenthedelayinrecruitment
of antigen-speciﬁc Th1 cells in the lungs is one of the central
improvements required in the development of eﬀective TB
vaccines.
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